Figure 3. Forced inhibition of SRPK1 expression in ovarian cancer cell lines enhances sensitivity to cisplatin.

Ovarian cancer cells were transiently (A) or stably (C) transfected with either the siRNA-encoding shSRPK1 plasmid or the empty vector (pSM2-EV). Protein levels of SRPK1, UPF1 and actin were determined by Western blot analysis. Representative blots from three independent experiments are shown. (B) and (D) SRPK1 knockdown enhances cisplatin cytotoxicity. (B) Cells (5×10⁴) were reseeded 24 h after transfection, treated with various concentrations of cisplatin for 48 hr and the number of surviving cells was analyzed by MTT assay. Survival (%) is expressed relative to non-treated pSM2-EV cells. (D) Stable transfectants (3×10²) were seeded in triplicate, treated with cisplatin for 24 hr and colony formation was assessed after 10–14 days. Data were analyzed with one way ANOVA and * indicates P<0.05; bars, SD.